Adropin, Insulin, Insulin Resistance and Lipid Profile Levels in Diabetes Mellitus Type2 Patients
Diabetes biomarkers
DOI:
https://doi.org/10.32441/ijms.6.3.4Keywords:
T2DM, Adropin, Insulin hormone, Insulin resistance, Lipid profileAbstract
Background: Type 2 diabetes mellitus (T2DM) is non-insulin-dependent diabetes or diabetes that affects adults, and it represents 90% of diabetics and it occurs as a result of insulin resistance and a defect in insulin production. We aimed to evaluate levels of adropin, insulin, insulin resistance and lipid profile levels in diabetes mellitus type2 patients.
Aim: The current study aimed to investigate the relationship between type 2 diabetes mellitus and liver and adipose tissue by measuring the level of secreted Hepatokines and a number of hormonal and biochemical parameters in men.
Materials and Methods: The study group include 60 men with type 2 diabetes mellitus and a control group of 30 healthy men. Proteins and biochemistry assays include Adropin levels, insulin, Fasting blood sugar, Insulin resistance indicators(HOMA-IR,HOMA-B,QUICKI),Total cholesterol, Triglycerides, High-density lipoprotein for cholesterol, Low-density lipoprotein for cholesterol, Very high-density lipoprotein for cholesterol, Phospholipid and Atherogenic index.
Results: There was a significant increase at (P≥0.05) in Adropin levels, Fasting blood sugar, Total cholesterol, triglycerides, High-density lipoprotein for cholesterol, Low-density lipoprotein for cholesterol, Very high-density lipoprotein for cholesteroland Phospholipid in type 2 diabetes mellitus men compared to control group. while insulin and HOMA-B show significant decrease at (P≥0.05) in type 2 diabetes mellitus men compared to control group. Atherogenic index, HOMA-IR and QUICKI didn’t show any significant difference between both groups.
Conclusions: We conclude from the results of the current study that there is a relationship between type 2 diabetes mellitus and liver dysfunctions through a secretion imbalance of Adropin that indicates an association between liver disease and type 2 diabetes mellitus. The metabolic imbalances or risks of insulin resistance can lead to hyperglycemia, dyslipidemia, and obesity.
References
Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature, 2019;576(7785):51-60.
Deacon C F. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Frontiers Endocrinol,2019; 10, 80.
Brown JC, Harhay MO, Harhay MN. The value of anthropometric measures in nutrition and metabolism: comment on anthropometrically predicted visceral adipose tissue and blood-based biomarkers: a cross-sectional analysis. Nutrition Metabolic Insights,2019; 12:1178638819831712.
Freeman AM, Pennings N. Insulin resistance. In StatPearls [Internet]. StatPearls Publishing. 2022.
Jain HR, Shetty V, Singh GS, Shetty SA. Study of lipid profile in diabetes mellitus. Int J Scientific Study,2016; 4(9):55-60.
Adetunji K, Ebesunun M, Olaifa S, Ladipo O. Decreased Plasma Adropin: A Possible Risk Factor for Metabolic Syndrome in Type 2 Diabetic Patients in South-West, Nigeria. J Med Lab Sci, 2020; 30(1):21-30.
Ghaffari MA, Payami SA, Payami S, Ashtary-Larky D, Nikzamir A, Mohammadzadeh G. Evaluation of Insulin Resistance Indices in Type 2 Diabetic Patients Treated with Different Anti-Diabetic Drugs. Open J Endocrine Metabolic Dis,2016;6:95-101.
Tietz NW. Textbook of clinical chemistry. W.B.Sanders Company, Philadelphia, USA.1999; 112-195.
Burtis CA, Ashwood ER. Textbook of clinical chemistry. 3rd ed. W. B. Saunders Company, Tokyo. 1999; pp:1034-1054.
Hosseini A, Shanaki M, Emamgholipour S, Nakhjavani M, Razi F, Golmohammadi T. Elevated serum levels of adropin in patients with type 2 diabetes mellitus and its association with insulin resistance. J Biol Today’s World, 2016; 5:44-49.
Es-Haghi A, Al-Abyadh T, Mehrad-Majd H. The Clinical Value of Serum Adropin Level in Early Detection of Diabetic Nephropathy. Kidney and Blood Pressure Research, 2021;46(6):734-740.
Saini, V. Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J Diabetes,2010; 1(3):68.
Ritzel RA, Butler AE, Rizza RA, Veldhuis JD, Butler PC. Relationship between β-cell mass and fasting blood glucose concentration in humans. Diabetes Care,2006; 29(3):717-718.
Ahmad M, Rachmawaty R, Sjattar EL, Yusuf S. Prolanis implementation effective to control fasting blood sugar, HBA1C and total cholesterol levels in patients with type 2 diabetes. Jurnal Ners,2017; 12(1):88-98.
Sabahelkhier MK, Awadllah MA, Idrees ASM, Rahheem AAGA. A study of lipid profile Levels of Type II Diabetes Mellitus. Nova J Med Biol Sci,2016; 5(2):1-9.
Hussain A, Ali I, Kaleem WA, Yasmeen F. Correlation between body mass index and lipid profile in patients with type 2 diabetes attending a tertiary care hospital in Peshawar. Pakistan J Med Sci,2019; 35(3):591.
Bhuyar BK. Lipid profile in diabetes mellitus. Int J Biotechnol Biochem,2017; 13(2): 123-131.
Hirano T. Pathophysiology of diabetic dyslipidemia. J Atherosclerosis Thrombosis,2018; 25(9):771-782.
Meikle PJ, Summers SA. Sphingolipids and phospholipids in insulin resistance and related metabolic disorders. Nature Rev Endocrin, 2017; 13(2):79-91.
Al-Hakeim HK, Abdulzahra MS. Correlation between glycated hemoglobin and homa indices in type 2 diabetes mellitus: prediction of beta-cell function from glycated hemoglobin. J Med Biochem, 2015; 34(2):191.
